- List
- By Topic
- On Map
- Search Details

Vortioxetine | "Depressive Disorder"
Need help? See RSS Feeds
Choose a feed type:

Vortioxetine | "Depressive Disorder" (49 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT01179516 | Completed Has Results |
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
469 | All | 18 Years to 75 Years (Adult, Senior) | NCT01179516 | LuAA21004_317 U1111-1116-3223 SU-06032011-7846 |
August 2010 | May 2012 | June 2012 | August 11, 2010 | December 18, 2013 | December 18, 2013 |
|
|
2 | NCT02972632 | Completed | Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder |
|
|
Interventional | Phase 4 |
|
Industry |
|
|
123 | All | 18 Years to 65 Years (Adult) | NCT02972632 | Vortioxetine-4003 U1111-1185-6902 |
December 22, 2016 | February 6, 2018 | February 6, 2018 | November 23, 2016 | February 13, 2018 |
|
||
3 | NCT01255787 | Completed Has Results |
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder |
|
|
Interventional | Phase 2 Phase 3 |
|
Industry |
|
|
600 | All | 20 Years to 64 Years (Adult) | NCT01255787 | LuAA21004/CCT-002 2010-022257-41 U1111-1117-6595 JapicCTI-101344 CTRI/2011/08/001963 |
November 2010 | March 2012 | April 2012 | December 7, 2010 | December 18, 2013 | December 18, 2013 |
|
|
4 | NCT01163266 | Completed Has Results |
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
462 | All | 18 Years to 75 Years (Adult, Senior) | NCT01163266 | LuAA21004_316 U1111-1115-8770 |
July 2010 | January 2012 | January 2012 | July 15, 2010 | December 18, 2013 | December 18, 2013 |
|
|
5 | NCT00672958 | Completed Has Results |
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
600 | All | 18 Years to 75 Years (Adult, Senior) | NCT00672958 | LuAA21004_303 U1111-1114-2328 |
April 2008 | November 2008 | November 2008 | May 6, 2008 | December 13, 2013 | December 13, 2013 |
|
|
6 | NCT00707980 | Completed Has Results |
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
836 | All | 18 Years to 76 Years (Adult, Senior) | NCT00707980 | LuAA21004_301 2008-001581-91 U1111-1113-9564 |
June 2008 | July 2010 | August 2010 | July 2, 2008 | December 13, 2013 | December 13, 2013 |
|
|
7 | NCT03108625 | Enrolling by invitation | Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
170 | All | 7 Years to 17 Years (Child) | NCT03108625 | 12712B 2015-002658-11 |
March 1, 2017 | October 2020 | October 2020 | April 11, 2017 | March 22, 2018 |
|
||
8 | NCT02371980 | Recruiting | Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder |
|
|
Interventional | Phase 4 |
|
Industry |
|
|
228 | All | 18 Years to 75 Years (Adult, Senior) | NCT02371980 | LuAA21004_402 U1111-1161-4956 |
February 18, 2015 | May 1, 2019 | May 1, 2019 | February 26, 2015 | February 13, 2018 |
|
||
9 | NCT02871297 | Enrolling by invitation | Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
850 | All | 7 Years to 18 Years (Child, Adult) | NCT02871297 | 12712A 2008-005356-25 |
August 2016 | April 2019 | April 2019 | August 18, 2016 | March 22, 2018 |
|
||
10 | NCT01323478 | Completed Has Results |
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
71 | All | 18 Years to 75 Years (Adult, Senior) | NCT01323478 | 13267B 2010-024198-38 |
April 2011 | September 2012 | October 2012 | March 25, 2011 | February 11, 2014 | February 11, 2014 | ||
11 | NCT00761306 | Completed Has Results |
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
74 | All | 18 Years to 65 Years (Adult) | NCT00761306 | 11492C 2007-000905-31 |
June 2007 | September 2008 | October 2008 | September 29, 2008 | January 29, 2014 | December 17, 2013 | ||
12 | NCT00735709 | Completed Has Results |
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
560 | All | 18 Years to 75 Years (Adult, Senior) | NCT00735709 | LuAA21004_305 2008-001580-11 U1111-1114-0326 |
August 2008 | July 2009 | August 2009 | August 15, 2008 | December 18, 2013 | December 18, 2013 |
|
|
13 | NCT00694304 | Completed Has Results |
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
535 | All | 18 Years to 75 Years (Adult, Senior) | NCT00694304 | 11984B EudraCT 2007-004992-21 |
May 2008 | March 2010 | April 2010 | June 10, 2008 | April 1, 2014 | April 1, 2014 | ||
14 | NCT01355081 | Completed Has Results |
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
366 | All | 20 Years to 75 Years (Adult, Senior) | NCT01355081 | LuAA21004/CCT-003 U1111-1120-9277 JapicCTI-111492 |
May 2011 | December 2012 | December 2012 | May 17, 2011 | November 11, 2014 | November 11, 2014 |
|
|
15 | NCT01153009 | Completed Has Results |
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
614 | All | 18 Years to 75 Years (Adult, Senior) | NCT01153009 | LuAA21004_315 U1111-1114-8191 |
June 2010 | March 2012 | March 2012 | June 29, 2010 | December 18, 2013 | December 18, 2013 |
|
|
16 | NCT00672620 | Completed Has Results |
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
611 | All | 18 Years to 75 Years (Adult, Senior) | NCT00672620 | LuAA21004_304 U1111-1114-3497 |
April 2008 | November 2008 | December 2008 | May 6, 2008 | December 18, 2013 | December 18, 2013 |
|
|
17 | NCT02272517 | Completed | Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
101 | All | 18 Years to 65 Years (Adult) | NCT02272517 | 15907A 2014-000231-16 |
December 2014 | March 2016 | March 2016 | October 23, 2014 | February 28, 2017 |
|
||
18 | NCT01488071 | Completed Has Results |
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
495 | All | 18 Years to 75 Years (Adult, Senior) | NCT01488071 | 14178A 2011-002362-21 |
REVIVE | January 2012 | December 2012 | December 8, 2011 | March 26, 2014 | March 26, 2014 | ||
19 | NCT02749721 | Recruiting | The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
50 | All | 18 Years to 65 Years (Adult) | NCT02749721 | IISR-2014-100702a | December 2016 | December 2018 | February 2019 | April 25, 2016 | March 30, 2018 |
|
||
20 | NCT01571453 | Completed Has Results |
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
437 | All | 18 Years to 65 Years (Adult) | NCT01571453 | 13926A | May 2012 | October 2013 | April 5, 2012 | October 13, 2014 | October 13, 2014 | |||
21 | NCT00811252 | Completed Has Results |
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
453 | All | 65 Years and older (Adult, Senior) | NCT00811252 | 12541A 2008-002901-38 |
January 2009 | February 2010 | March 2010 | December 18, 2008 | January 29, 2014 | December 18, 2013 | ||
22 | NCT02709746 | Recruiting | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
750 | All | 12 Years to 17 Years (Child) | NCT02709746 | 12710A 2008-005354-20 |
May 2016 | October 2018 | October 2018 | March 16, 2016 | March 22, 2018 |
|
||
23 | NCT02279953 | Completed | Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
151 | All | 18 Years to 65 Years (Adult) | NCT02279953 | 15905A 2014-000229-19 |
October 2014 | April 2016 | April 2016 | October 31, 2014 | May 24, 2017 |
|
||
24 | NCT02279966 | Completed | Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
152 | All | 18 Years to 65 Years (Adult) | NCT02279966 | 15906A 2014-000230-34 |
October 2014 | February 2016 | February 2016 | October 31, 2014 | February 28, 2017 |
|
||
25 | NCT01422213 | Completed Has Results |
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
598 | All | 18 Years to 65 Years (Adult) | NCT01422213 | 14122A 2011-001572-19 |
FOCUS | December 2011 | May 2013 | August 23, 2011 | August 5, 2014 | August 5, 2014 | ||
26 | NCT02919501 | Completed | Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
55 | All | 18 Years to 65 Years (Adult) | NCT02919501 | 16903A 2015-005081-30 |
September 27, 2016 | April 27, 2017 | April 27, 2017 | September 29, 2016 | July 7, 2017 |
|
||
27 | NCT02454426 | Withdrawn | Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease |
|
|
Interventional | Early Phase 1 |
|
Other / Industry |
|
|
0 | All | 18 Years to 75 Years (Adult, Senior) | NCT02454426 | TakedaHRV | April 2016 | June 2016 | June 2016 | May 27, 2015 | August 25, 2016 |
|
||
28 | NCT02389816 | Completed | A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
492 | All | 20 Years to 75 Years (Adult, Senior) | NCT02389816 | LuAA21004/CCT-004 U1111-1167-1520 JapicCTI-152831 |
April 10, 2015 | March 16, 2018 | March 16, 2018 | March 17, 2015 | March 30, 2018 |
|
||
29 | NCT01140906 | Completed Has Results |
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
607 | All | 18 Years to 75 Years (Adult, Senior) | NCT01140906 | 13267A 2009-017523-26 |
May 2010 | September 2011 | June 10, 2010 | February 11, 2014 | February 11, 2014 | |||
30 | NCT01395147 | Completed | Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
119 | All | 20 Years to 75 Years (Adult, Senior) | NCT01395147 | LuAA21004/OCT-001 JapicCTI-111530 U1111-1122-3910 |
July 2011 | May 2013 | May 2013 | July 15, 2011 | November 5, 2013 |
|
||
31 | NCT02709655 | Recruiting | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
750 | All | 7 Years to 11 Years (Child) | NCT02709655 | 12709A 2008-005353-38 |
May 2016 | October 2018 | October 2018 | March 16, 2016 | March 22, 2018 |
|
||
32 | NCT00635219 | Completed Has Results |
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
766 | All | 18 Years to 75 Years (Adult, Senior) | NCT00635219 | 11984A EudraCT 2007-001870-95 |
February 2008 | April 2009 | April 2009 | March 13, 2008 | February 11, 2014 | February 11, 2014 | ||
33 | NCT01152996 | Completed Has Results |
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
1075 | All | 18 Years to 77 Years (Adult, Senior) | NCT01152996 | LuAA21004_314 U1111-1115-4927 |
September 2010 | May 2013 | May 2013 | June 29, 2010 | May 28, 2014 | May 28, 2014 | ||
34 | NCT01564862 | Completed Has Results |
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
602 | All | 18 Years to 65 Years (Adult) | NCT01564862 | LuAA21004_202 2011-005298-22 U1111-1126-0091 |
April 2012 | February 2014 | February 2014 | March 28, 2012 | February 5, 2015 | February 5, 2015 |
|
|
35 | NCT01607125 | Completed | Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
96 | All | 25 Years to 55 Years (Adult) | NCT01607125 | 14137A 2011-001839-23 |
July 2012 | September 2013 | May 28, 2012 | September 25, 2013 |
|
|||
36 | NCT00839423 | Completed Has Results |
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
426 | All | 18 Years to 65 Years (Adult) | NCT00839423 | 11492A 2006-001515-29 |
August 2006 | August 2007 | September 2007 | February 9, 2009 | May 13, 2014 | December 17, 2013 | ||
37 | NCT02332954 | Completed | Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine |
|
|
Interventional | Phase 4 |
|
Industry |
|
|
226 | All | 18 Years to 65 Years (Adult) | NCT02332954 | 15913A | AtWoRC | February 2015 | July 6, 2017 | July 6, 2017 | January 7, 2015 | January 30, 2018 |
|
|
38 | NCT00596817 | Completed Has Results |
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
639 | All | 18 Years to 75 Years (Adult, Senior) | NCT00596817 | 11985A 2007-001871-13 |
December 2007 | September 2009 | October 2009 | January 17, 2008 | March 31, 2014 | March 31, 2014 | ||
39 | NCT03053362 | Not yet recruiting | THINC-it Vortioxetine - Sensitivity to Change |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
150 | All | 18 Years to 65 Years (Adult) | NCT03053362 | Pro00020418 | March 2017 | September 2018 | September 2018 | February 15, 2017 | February 15, 2017 | |||
40 | NCT02294305 | Active, not recruiting | Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder |
|
|
Interventional | Phase 4 |
|
Other |
|
|
40 | All | 18 Years to 70 Years (Adult, Senior) | NCT02294305 | TAK-S001560 | December 2014 | November 2016 | November 2016 | November 19, 2014 | August 24, 2016 |
|
||
41 | NCT02845349 | Withdrawn | Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI) |
|
|
Interventional | Phase 3 |
|
Other / Industry |
|
|
0 | All | 18 Years and older (Adult, Senior) | NCT02845349 | IRB00105196 | October 2016 | October 2018 | October 2018 | July 27, 2016 | September 2, 2016 | |||
42 | NCT01364649 | Completed Has Results |
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
447 | All | 18 Years to 55 Years (Adult) | NCT01364649 | LuAA21004_318 U1111-1120-3483 |
June 2011 | December 2013 | December 2013 | June 2, 2011 | October 9, 2014 | October 9, 2014 |
|
|
43 | NCT02234362 | Completed Has Results |
Vortioxetine for Menopausal Depression |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
47 | Female | 40 Years to 62 Years (Adult) | NCT02234362 | 2014P001812 | June 12, 2015 | September 29, 2016 | September 29, 2016 | September 9, 2014 | June 28, 2017 | May 2, 2017 |
|
|
44 | NCT03187093 | Recruiting | Cognitive Dysfunction in MDD Patients |
|
|
Interventional | Phase 4 |
|
Other |
|
|
150 | All | 20 Years to 60 Years (Adult) | NCT03187093 | 11031215 | October 2016 | July 2018 | September 2018 | June 14, 2017 | June 16, 2017 |
|
||
45 | NCT02637466 | Withdrawn | Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
0 | Female | 18 Years to 75 Years (Adult, Senior) | NCT02637466 | 20150753 | July 2016 | July 2018 | July 2019 | December 22, 2015 | September 30, 2016 | |||
46 | NCT01491035 | Completed Has Results |
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
48 | All | 7 Years to 17 Years (Child) | NCT01491035 | 12708A 2010-020170-42 |
April 2012 | December 2014 | June 2015 | December 13, 2011 | March 16, 2017 | January 15, 2016 |
|
|
47 | NCT02969876 | Recruiting | Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
20 | All | 18 Years to 65 Years (Adult) | NCT02969876 | 2016P001243 | VOR-IISR | November 2016 | November 2017 | November 2017 | November 21, 2016 | November 21, 2016 |
|
|
48 | NCT03485274 | Not yet recruiting New |
Substance Misuse To Psychiatric Disorders for Cannabis |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
70 | All | 16 Years to 30 Years (Child, Adult) | NCT03485274 | SToP-C | May 1, 2018 | May 31, 2019 | August 1, 2019 | April 2, 2018 | April 3, 2018 | |||
49 | NCT02883660 | Completed | Genecept Assay and Adverse Effects of Antidepressants |
|
|
Observational |
|
Other |
|
|
74 | All | 18 Years and older (Adult, Senior) | NCT02883660 | 13P.25 | February 2013 | July 1, 2017 | February 1, 2018 | August 30, 2016 | March 16, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.